Search
Grand Pharmaceutical Achieves Milestone: Innovative Nuclear Drug TLX591 Approved for International Multicenter Phase III Clinical Trial
2 week ago /
Read about 0 minute
Author：小编
Grand Pharmaceutical has proudly announced that its groundbreaking radionuclide-conjugated drug, TLX591, for the treatment of prostate cancer, has secured approval from the National Medical Products Administration of China to commence an international, multicenter Phase III clinical trial. This trial will enlist over 500 patients from China, the United States, Australia, New Zealand, Europe, and other regions, with the objective of evaluating the efficacy and safety of TLX591 in combination with standard therapy, as compared to standard therapy alone, in patients with metastatic castration-resistant prostate cancer who have progressed after androgen receptor pathway inhibitor therapy.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
